RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase A, members will obtain distinct doses and schedules of oral ABBV-744 pill to determine Secure dosing program. More members is going to be enrolled on the identified monotherapy dosign routine. In Segment B, participants will acquire oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Section C, contributors will acqu